ArticleDiscover oncology2025
NTRK expression and its clinical significance in pancreatic neuroendocrine tumors.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comprehensive Clinicopathologic, Immunohistochemical, and Genomic Profiling of Sporadic Ampullary Somatostatin-producing D-cell Neuroendocrine Tumors Identifies Recurrent HRAS Hotspot Mutations.Endocrine pathology · 2026Article
- Fusion-Negative NTRK Overexpression Exhibit Biological Relevance in Colorectal Cancer: Implications for Prediction of Responses to Kinase Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe neurotrophic TRK family, which includes NTRK1, 2, and 3, could be the oncogenic driving force in various cancers, when they undergo fusion mutations with other genes and form a chimeric oncoprotein. In our study, we aimed to explore the expression and gene alterations of NTRK in pancreatic neuroendocrine tumors (pNETs).
methodsImmunohistochemistry (IHC) staining was utilized to assess NTRK expression in pNETs, using pan-TRK cocktail (clone LBP2-NTRK). Any intensity of staining in ≥ 1% of tumor cells was classified as positive. IHC-positive specimens then underwent Fluorescence In Situ Hybridization (FISH) analysis, using the NTRK1-3 gene fragmentation probe. Clinical data were obtained through retrospective chart review.
resultsNTRK expression was observed in 16.7% (7/42) of pNETs: 4 patients were females and 3 were males; 6 were over 50 years old, with only one patient aged 29 years; 3 tumors were WHO G1, 3 were G2 and 1 was G3. Lymphovascular invasion was identified in 3 cases. No NTRK expression was detected in any of the 8 cases with liver-metastatic pNETs. No statistically significant difference was identified between the NTRK-expression and the clinicopathological parameters, such as the age, tumor location, tumor size, tumor grade, lymphovascular invasion, metastatic disease, and the expression of MGMT and SSTR2. Furthermore, no NTRK fusions were identified in any of the 7 cases by FISH analysis.
conclusionsOur data suggest that NTRK expression could be present in some pNETs, but not associated with its gene translocation. The pathophysiology of this phenotype is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.